Replimune Group Hosts Investor Day for Updates

The latest announcement is out from Replimune Group ( (REPL) ).

Replimune Group, Inc. held an Investor Day on June 24, 2025, to provide updates to investors, with materials available on their website. The company emphasizes using its website for investor information and compliance with disclosure obligations.

The most recent analyst rating on (REPL) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Replimune Group stock, see the REPL Stock Forecast page.

Spark’s Take on REPL Stock

According to Spark, TipRanks’ AI Analyst, REPL is a Neutral.

Replimune Group’s stock score reflects its early-stage status in the biotechnology sector, characterized by significant R&D investments leading to negative earnings and cash flows. While the company shows strong equity, the current technical indicators suggest mixed to bearish market momentum. Valuation remains challenging due to negative earnings. The company’s future success hinges on the development and commercialization of its products.

To see Spark’s full report on REPL stock, click here.

More about Replimune Group

Replimune Group, Inc. operates in the biotechnology industry, focusing on the development of oncolytic immunotherapies for cancer treatment.

Average Trading Volume: 1,166,729

Technical Sentiment Signal: Sell

Current Market Cap: $714.6M

See more data about REPL stock on TipRanks’ Stock Analysis page.